New drug shows promise for rare HER2-Mutated cancers
NCT ID NCT04639219
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a drug called trastuzumab deruxtecan (T-DXd) in 102 adults with advanced solid tumors that have specific HER2 mutations. The cancers include types like colorectal, gastric, and ovarian, among others. The goal is to see if the drug can shrink tumors or slow their growth. Participants must have already tried other treatments or have no good options left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (T-DXd)
What this could lead to
If successful, this could provide a new treatment option for people with hard-to-treat cancers that have specific HER2 mutations, regardless of where the cancer started.
What could go wrong
This is a mid-stage trial with only 102 participants and no comparison group. The drug may not work for all mutation types, and side effects like lung inflammation or heart problems are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Santa Rosa, California, 95403, United States
-
Research Site
Muncie, Indiana, 47303, United States
-
Research Site
Boston, Massachusetts, 02115, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Middletown, New Jersey, 07748, United States
-
Research Site
Commack, New York, 11725, United States
-
Research Site
Harrison, New York, 10604, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Anderlecht, 1070, Belgium
-
Research Site
Toronto, CA, M5G 2M9, Canada
-
Research Site
Copenhagen, 2100, Denmark
-
Research Site
Bordeaux, 33076, France
-
Research Site
Lyon, 69008, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Milan, 20141, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Suita-shi, 565-0871, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Madrid, 28050, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Seville, 41013, Spain